Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Techne (TECH) Share-based Compensation (2016 - 2025)

Bio-Techne (TECH) has 17 years of Share-based Compensation data on record, last reported at $14.0 million in Q4 2025.

  • For Q4 2025, Share-based Compensation fell 5.1% year-over-year to $14.0 million; the TTM value through Dec 2025 reached $41.6 million, up 3.72%, while the annual FY2025 figure was $40.8 million, 7.34% up from the prior year.
  • Share-based Compensation reached $14.0 million in Q4 2025 per TECH's latest filing, up from $11.7 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $16.7 million in Q4 2022 and bottomed at -$2.1 million in Q2 2023.
  • Average Share-based Compensation over 5 years is $10.3 million, with a median of $10.4 million recorded in 2021.
  • Peak YoY movement for Share-based Compensation: crashed 124.8% in 2023, then soared 438.75% in 2024.
  • A 5-year view of Share-based Compensation shows it stood at $14.0 million in 2021, then grew by 19.87% to $16.7 million in 2022, then fell by 23.84% to $12.8 million in 2023, then rose by 15.33% to $14.7 million in 2024, then decreased by 5.1% to $14.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $14.0 million in Q4 2025, $11.7 million in Q3 2025, and $4.6 million in Q2 2025.